Objective To study the curative effect and clinical safety of gimeracil and oteracil potassium combined with oxaliplatin in treatment of advanced gastric carcinoma patients.Methods From January 2009 to December 2011,116 cases with advanced gastric carcinoma were randomly chosen and divided into group A,B (58 cases in each group).Group A was given gimeracil and oteracil potassium combined with oxaliplatin,while group B was given oxaliplatin,fluorouracil and calcium folinate.Before and after dosing,the blood routine,liver and kidney function,chest CT scanning and gastroscope inspection were observed,the recent curative effect and adverse reaction of chemotherapy were analyzed.The patients' survival time and disease progression were compared.Results The curative effect of 116 patients could all be evaluated,and the effective rate of group A and group B were 48.3％(28/58) and 29.3％(17/58),while clinical benefit rate were 74.1％(43/58) and 55.2％(32/58),there was significant difference(P ＜ 0.05).The survival rate of two groups at different time points had no significant difference (P ＞0.05).The rate of nauseated and vomiting were 34.5％(20/58),37.9％(22/58) in group A,and 67.2％(39/58),62.1％(36/58) in group B,there was significant difference (P ＜ 0.05).The influence of drugs on blood system,common peripheral neurotoxicity,extremities syndrome and inflammation of the oral mucosa between two groups had no significant difference (P ＞0.05).Conclusions Gimeracil and oteracil potassium combined with oxaliplatin in treatment of advanced gastric carcinoma patients has better clinical effect and less complication,which is worthy of further promotion.

Objective:To observe the sensitivities of breast cancer cells and its implanted tumors to chemotherapeutic drug epirubicin after down-regulation of HER-2 expression by RNA interference(RNAi).Methods:HER-2siRNApU6 vector containing HER-2 RNAi was constructed and was used to transfect HER-2 positive breast cancer cell line SKBR-3.The expression of HER-2 mRNA and protein were analyzed by RT-PCR and Western blotting,respectively.Transfected SKBR-3 cells were treated with different concentrations of epirubicin;the growth of SKBR-3 cells and IC50 of epirubicin were observed by MTT.SKBR-3 cells were injected into nude mouse to establish breast cancer model;the sensitivity of mouse model to epirubicin was observed after HER-2shRNApU6 treatment.Results:Expression of HER-2 mRNA and HER-2 protein were down-regulated in SKBR-3 cells after transfection with HER-2shRNApU6.Furthermore,the proliferation of SKBR-3 cells transfected with HER-2shRNApU6 was significantly decreased compared with mock tansfected group(P

Objective To analyse the frequeney and pattern of lymph node metastasis in bilateral papillary thyroid microcarcinoma (PTMC), and establish the optimal surgical strategy for patients. Methods From March 2006 to August 2008, 58 bilateral PTMC patients received surgical treatment and the tumour characteristics, the frequency and pattern of lymph node metastasis and surgical management of these patients were retrospectively analysed. Results Forty-four patients received total thyroideetomy and 14 patients received near-totsl thyroideetomy, 47 patients received central compartment (level VI ) dissection and cervical level Ⅱ,Ⅲ, IV node exploration by internal jugular vein exposure,10 patients received level Ⅵdissection and unilateral cervical dissection and 1 patient received bilateral cervical dissection. The mean tumor diameter was (6.28 + 2.23) mm and 26 patients (44.8%) had node involvement, 88.5%(23/26) pa-tients had only level Ⅵ node involvement. Only 1 patient had node involvement in the jugular chain without level Ⅵ node involvement, 2 patients with level Ⅵ node involvement were associated with another cervical compartment nodes involvement. Conclusions Bilateral PTMC has high incidence of lymph node metasta-sis. The cervical level Ⅵ is the most common site of node involvement for bilateral PTMC and the surgical strategy for bilateral PTMC should include the cervical level Ⅵ dissection routinely.

Objective To evaluate the value of contrast-enhanced uhrasound(CEUS)for liver fibrosis.Methods Ninty-two chronic hepatitis B patients with histology diagnosis and fifteen health control were detected by CEUS,dynamic images and the time-intensity curve were analyed.Results Hepatic veinartery transit(HV-ATT)became shorter in the early hepatic cirrhosis patients [(7.5±2.1)s]compared to the control[(11.8±2.7)s].However,there was no difference between the fibrosis patients [(13.0±2.2)s]and the control.Furthermore,HV-ATT of the fibrosis patients with S1 to S3 stage were(11.7±2.7)s(S1),(11.8±3.0)S(S2),(11.8±2.3)s(S3)without significant difference.Conclusions CEUS is valuable in diagnosing earlier hepatic cirrhosis,but not fibrosis.

To verify the reliability of targeted detecting HER2 positive cancer cells and clinical pathological tissue specimens with a recombinant anti HER2 single chain antibody in single chain Fv fragment (scFv) format, we have constructed the fusion variable regions of the ScFv specific for HER2/neu. labeled a green-fluorescent protein(GFP). The humanized recombinant Anti HER2 ScFv-GFP gene was inserted into pFast Bac HT A, and expressed in insect cells sf9. Then the recombinant fusion protein Anti HER2 ScFv-GFP was properly purified with Ni2+-NTA affinity chromatography from the infected sf9 cells used to test the specificity of the fusion antibody for HER2 positive cancer cells. Firstly, the purified antibody incubated with HER2 positive breast cancer cells SKBR3, BT474 and HER2 negative breast cancer cells MCF7 for 12 h/24 h/48 h at 37 degrees C, in order to confirm targeted detecting HER2 positive breast cancer cells by Laser Confocal Microscopy. Furthermore, the same clinical pathological tissue samples were assessed by immunohistochemistry (IHC) and the fusion antibody Anti HER2 ScFv-GFP in the meanwhile. The data obtained indicated that the recombinant eukaryotic expression plasmid pFast Bac HT A/Anti HER2 ScFv-GFP was constructed successfully In addition, obvious green fluorescent was observed in insect cells sf9. When the purified fusion antibody was incubated with different cancer cells, much more green fluorescent was observed on the surface of the HER2 positive cancer cells SKBR3 and BT474. In contrast, no green fluorescent on the surface of the HER2 negative cancer cells MCF7 was detected. The concentration of the purified fusion antibody was 115.5 microg/mL, of which protein relative molecular weight was 60 kDa. The analysis showed the purity was about 97% and the titer was about 1:64. The detection results of IHC and fusion antibody testing indicated the conformity. In summary, the study showed that the new fusion antibody Anti HER2 ScFv-GFP can test HER2 positive cancer cells, indicating a potential candidate method for clinical HER2 positive specimens detection.
Animals ; Breast Neoplasms ; diagnosis ; pathology ; Female ; Genetic Vectors ; genetics ; Green Fluorescent Proteins ; genetics ; Humans ; MCF-7 Cells ; Receptor, ErbB-2 ; analysis ; Recombinant Fusion Proteins ; genetics ; Sf9 Cells ; Single-Chain Antibodies ; genetics